URL copied
COVID-19 vaccine race: Where they stand currently
Almost a year into the COVID-19 pandemic, about 200 vaccine candidates are in the works and 10 have been either approved by several countries or are under limited emergency use. As India prepares to launch its vaccine drive on January 16, here is a look at the options:
COVAXIN
Developed by Bharat Biotech in collaboration with the Indian Council of Medical Research and the National Institute of Virology, the indigenous vaccine was granted emergency use authorisation in âclinical trial modeâ by the Indian government this week.
It is an âinactivatedâ vaccine developed by chemically treating novel coronavirus samples to make them incapable of reproduction. This process leaves the viral proteins, including the spike protein of the coronavirus which it uses to enter the human cells, intact.Â
Developed by Bharat Biotech in collaboration with the Indian Council of Medical Research and the National Institute of Virology, the indigenous vaccine was granted emergency use authorisation in clinical trial mode by the Indian government this week.
Almost a year into the COVID-19 pandemic, about 200 vaccine candidates are in the works and 10 have been either approved by several countries or are under limited emergency use.
Coronavirus | Use of a vaccine without knowing its protection potential is unethical, says immunologist Vineeta Bal
Updated:
Updated:
January 08, 2021 23:55 IST
Dr. Bal, a former scientist of the National Institute of Immunology, says emergency use approval for COVID-19 vaccines over fears of mutant strains is not reasonable on a scientific basis.
Share Article
Dr. Vineeta Bal. File
Dr. Bal, a former scientist of the National Institute of Immunology, says emergency use approval for COVID-19 vaccines over fears of mutant strains is not reasonable on a scientific basis.
Dr. Vineeta Bal
, immunologist and Faculty, Indian Institute of Science Education and Research (IISER), Pune, and former scientist, National Institute of Immunology, New Delhi, disagrees with the emergency use approval given to Covaxin, the COVID-19 vaccine by Bharat Biotech, on the grounds that there was no evidence yet on if and how it provided protection. Excerpts from an interview with The Hindu’s